西妥昔单抗联合吉西他滨对三阴性乳腺癌细胞增殖及凋亡的影响
The effect of cetuximab combined with gemcitabine on the proliferation and apoptosis of triple negative breast cancer cells
-
摘要: 目的:研究表皮生长因子受体的单克隆抗体西妥昔单抗与吉西他滨联合应用对三阴性乳腺癌MDA-MB-231细胞的增殖和凋亡的影响。方法:使用不同浓度药物联合处理MDA-MB-231细胞,四甲基偶氮唑蓝法检测药物的生长抑制效应;碘化丙啶染色流式细胞仪检测细胞凋亡;Western blot测定MDA-MB-231细胞bcl-2家族蛋白表达。结果:75g/ml的西妥昔单抗与10mol/L的吉西他滨联合作用于MDA-MB-231细胞的48 h存活率为48.53%;75g/ml的西妥昔单抗与2mol/L的吉西他滨联合用药诱导的细胞凋亡率为45.7%,较单用吉西他滨的凋亡率16.5%明显提高(P0.01);单用吉西他滨可以使蛋白bcl-2表达下调,合用后较单用下调更加明显。结论:西妥昔单抗与吉西他滨对三阴性乳腺癌MDA-MB-23细胞有抑制增殖及促进凋亡的作用,两者联合表现为相加或协同作用。Abstract: Objective: To investigate the antitumor effects of cetuximab of the epidermal growth factor receptor monoclonal antibody combined with gemcitabine on triple negative breast cancer MDA-MB-231 cells. Methods: The growth inhibitory and apoptosis of MDAMB-231 cells treated with different concentration drugs were detected by MTT and flow cytometry PI staining,respectively. The bcl-2 expression in MDA-MB-231 cells were detected by western blot. Results: The survival rate of MDA-MB-231 cells treated with 75 g / ml of cetuximab combined with 10 mol / L gemcitabine for 48 h was 48. 53%. The apoptosis rate of MDA-MB-231 cells treated with 75 g / ml of cetuximab combined with 2 mol / L of gemcitabine( 45. 7%) was significantly higher than that in these cells treated with cetuximab alone( 16. 5%)( P 0. 01). The bcl-2 expression in MDA-MB-231 cells treated with gemcitabine was downregulated,the downregulation of which was more obvious after combination with other drugs. Conclusions: The cetuximab combined with gemcitabine in the treatment of triple negative breast cancer MDA-MB-231 cells can inhibit proliferation and promote apoptosis,a combination of two drugs show additive or synergistic effect.
-
Key words:
- breast neoplasms /
- cetuximab /
- gemcitabine /
- cell proliferation /
- apoptosis
-
[1] Yin WJ, Lu JS, Di GH, et al. Clinicopathologcal features of the triple-negative tumors in Chinese breast cancer patients[J]. Breast Cancer Res Treat, 2007, 109(1):25 -32. [2] Reis-Filho JS, Futt AN. Triple negative tumours:a critical review[J]. Histopathol, 2008, 52(1):108 -118. [3] Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breastcancer and obesity in a rural Appalachian population[J]. CancerEpidemiol Biomarkers Prev, 2008, 17(12):3319 -3324. [4] Jang SM, Han H, Jang KS, et al. The glycolytic phenotype is correlated with aggressiveness and poor prognosis in invasive ductal carcinomas[J]. Breast Cancer, 2012, 15(2):172 -180. [5] Di Bonito M, Cantile M, Collina F, et al. Overexpression of cell cycle progression inhibitor geminin is associated with tumor stem-like phenotype of triple-negative breast cancer [J]. Breast Cancer, 2012, 15(2):162 -171. [6] Bartsch R, Ziebermayr R, Christoph C, et al. Triple-negative breast cancer[J]. Wien Medwochenschr, 2010, 160 ( 7/8 ):174 -181. [7] Hoadlcy KA, Weigman VJ, Fan C, et al. EGFB associated expression profiles vary with breast tumor subtype[J]. BMC Genom ics, 2007, 8:258. [8] Garey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative( basal-like) breast cancer[J]. Clin Oncol, 2008, 26(15):1009. [9] Gholam D, Chebib A, Hauteville D, et al. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative ( triplenegative)breast cancer[J]. Anticancer Drugs, 2007, 18 (7):835 -837. [10] Cheng X, Liu H, Fang L, et al. 2-DG enhances chemosensitivity of breast cancer cells to adriamycin[J]. Chin Pharmacol Bull, 2010, 26(10):1371 -1376. [11] Liu H, Jiang CC, Lavis CJ, et al. 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2[J]. Mol Cancer, 2009, 14(8):122. [12] Boopalan T, Arumugam A, Damodaran C, et al. The Anticancer effect of 2'-3'-dehydrosalannol on triple-negative breast cancer cells[J]. Anticancer Res, 2012, 32(7):2801 -2806. [13] Zhao HM, Zhang B, Li Y, et al. Effect of gefitinib on the migration of triple-negative breast cancer cell line MDA-MB-231 cells[J]. Zhonghua Zhong Liu Za Zhi, 2012, 34(2):84 -88.
计量
- 文章访问数: 3338
- HTML全文浏览量: 401
- PDF下载量: 156
- 被引次数: 0